- Fully dosed randomized, double-blind n=90 Part A cohort evaluating Annamycin with cytarabine for R/R AML.
- Management confirms data readout remains on track for Q1 2027 to select Part B dose.
- Blinded interim reviews show continued absence of cardiotoxicity.
?? Positive AI Sentiment (+2.5 / 10)